石药集团(01093.HK) 公布,集团开发的SYH2046片获中国国家药品监督管理局批准,在内地开展临床试验。该产品是一款具有完全自主知识产权的全新结构first-in-class小分子药物,本次获批的临床试验适应症为急性心肌梗死后心力衰竭。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-11 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.